1H7 (targeting N-cadherin EC1–3) and 2A9 (targeting N-cadherin EC4) are newfound antibodies targeting N-cadherin and have been proved effectiveness in treating prostate cancer in mouse model. Here, CDH2 is linked to prostate cancer.